Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable

Vinay Prasad, Victoria Kaestner

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Nivolumab (Opdivo, Bristol Meyer Squibb, New York, NY) and pembrolizumab (Keytruda, Merck, Kenilworth, NJ) are the first two US Food and Drug Administration (FDA)-approved monoclonal antibodies targeting programmed death-1 (PD-1). Nivolumab and pembrolizumab work by interfering with the interaction between PD-1 and programmed death ligand-1 (PD-L1), whose unimpeded interaction downregulates T cells allowing cancer cells to evade immune surveillance. These drugs have earned a series of FDA approvals for melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), urothelial cancer, classical Hodgkin lymphoma, and renal cell cancer. In this review we will summarize the data for efficacy and toxicity for these two agents. We conclude that they represent two valuable but interchangeable alternatives to target their approved indications. We will discuss how this can help global payers seeking to contain the cost of cancer therapeutics that continues to spiral out of control.

Original languageEnglish (US)
JournalSeminars in Oncology
DOIs
StateAccepted/In press - 2017

Fingerprint

Cell Death
Monoclonal Antibodies
United States Food and Drug Administration
Head and Neck Neoplasms
CD274 Antigen
Drug Approval
Squamous Cell Neoplasms
Neoplasms
Hodgkin Disease
Renal Cell Carcinoma
Non-Small Cell Lung Carcinoma
Melanoma
Down-Regulation
T-Lymphocytes
Costs and Cost Analysis
Pharmaceutical Preparations
nivolumab
pembrolizumab
Therapeutics

Keywords

  • Drug manufacturing
  • Me-too drugs
  • Nivolumab
  • Pembrolizumab

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

@article{c93556233b21495a9fb3e3f292bb4c48,
title = "Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable",
abstract = "Nivolumab (Opdivo, Bristol Meyer Squibb, New York, NY) and pembrolizumab (Keytruda, Merck, Kenilworth, NJ) are the first two US Food and Drug Administration (FDA)-approved monoclonal antibodies targeting programmed death-1 (PD-1). Nivolumab and pembrolizumab work by interfering with the interaction between PD-1 and programmed death ligand-1 (PD-L1), whose unimpeded interaction downregulates T cells allowing cancer cells to evade immune surveillance. These drugs have earned a series of FDA approvals for melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), urothelial cancer, classical Hodgkin lymphoma, and renal cell cancer. In this review we will summarize the data for efficacy and toxicity for these two agents. We conclude that they represent two valuable but interchangeable alternatives to target their approved indications. We will discuss how this can help global payers seeking to contain the cost of cancer therapeutics that continues to spiral out of control.",
keywords = "Drug manufacturing, Me-too drugs, Nivolumab, Pembrolizumab",
author = "Vinay Prasad and Victoria Kaestner",
year = "2017",
doi = "10.1053/j.seminoncol.2017.06.007",
language = "English (US)",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Nivolumab and pembrolizumab

T2 - Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable

AU - Prasad, Vinay

AU - Kaestner, Victoria

PY - 2017

Y1 - 2017

N2 - Nivolumab (Opdivo, Bristol Meyer Squibb, New York, NY) and pembrolizumab (Keytruda, Merck, Kenilworth, NJ) are the first two US Food and Drug Administration (FDA)-approved monoclonal antibodies targeting programmed death-1 (PD-1). Nivolumab and pembrolizumab work by interfering with the interaction between PD-1 and programmed death ligand-1 (PD-L1), whose unimpeded interaction downregulates T cells allowing cancer cells to evade immune surveillance. These drugs have earned a series of FDA approvals for melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), urothelial cancer, classical Hodgkin lymphoma, and renal cell cancer. In this review we will summarize the data for efficacy and toxicity for these two agents. We conclude that they represent two valuable but interchangeable alternatives to target their approved indications. We will discuss how this can help global payers seeking to contain the cost of cancer therapeutics that continues to spiral out of control.

AB - Nivolumab (Opdivo, Bristol Meyer Squibb, New York, NY) and pembrolizumab (Keytruda, Merck, Kenilworth, NJ) are the first two US Food and Drug Administration (FDA)-approved monoclonal antibodies targeting programmed death-1 (PD-1). Nivolumab and pembrolizumab work by interfering with the interaction between PD-1 and programmed death ligand-1 (PD-L1), whose unimpeded interaction downregulates T cells allowing cancer cells to evade immune surveillance. These drugs have earned a series of FDA approvals for melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), urothelial cancer, classical Hodgkin lymphoma, and renal cell cancer. In this review we will summarize the data for efficacy and toxicity for these two agents. We conclude that they represent two valuable but interchangeable alternatives to target their approved indications. We will discuss how this can help global payers seeking to contain the cost of cancer therapeutics that continues to spiral out of control.

KW - Drug manufacturing

KW - Me-too drugs

KW - Nivolumab

KW - Pembrolizumab

UR - http://www.scopus.com/inward/record.url?scp=85028355340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028355340&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2017.06.007

DO - 10.1053/j.seminoncol.2017.06.007

M3 - Article

C2 - 28923211

AN - SCOPUS:85028355340

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

ER -